4 viral envelope with human hepatoma cells or primary human hepatocytes. Moreover, the use 1 of transgenic immunodeficient mice with hepatocyte-lethal phenotype (Alb-uPA/SCID [13] 2 and Fah/Rag2/IL2r mice [14] ) that can be successfully transplanted with primary human 3 hepatocytes allowed to establish a small animal model to study certain aspects of HCV 4 infection in vivo [15, 16] .
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To date, the sequence of events leading from HCV-interaction with host factors on the 
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An alternative route of entry and spread by cell-cell transmission
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CD81 is one of these potential targets. Imidazole based compounds mimicking an 5 alpha helix in the LEL of CD81 compete for HCV E2-CD81 binding. These drugs bind E2 in a 6 reversible manner and block E2-CD81 interaction while having no effect on CD81 expression 
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Further characterization of the role of this host cell factor in the HCV entry process may lead 10 to designing compounds interfering with OCLN and inhibiting HCV entry.
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In addition to cell surface expressed host factors, HCV internalization and fusion are (Table 1) . Arbidol is a broad-spectrum antiviral that has already been evaluated in humans 
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